Blood tests may reveal why some pancreatic neuroendocrine tumors resist Second-Line treatment
NCT ID NCT07835893
First seen Sep 23, 2026 · Last updated Sep 24, 2026 · Updated 1 time
Summary
Researchers are studying adults with pancreatic neuroendocrine tumors that have spread to the liver and stopped responding to first-line treatment. Participants receive either lenvatinib plus chemotherapy or chemotherapy alone, based on their care plan. The team tracks tumor response, survival, and side effects, and analyzes blood samples for clues about why some tumors resist treatment. The goal is to find markers that predict who benefits from which second-line approach.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- lenvatinib combined with chemotherapy
- What this could lead to
- If the combination works better than chemotherapy alone, it could offer a stronger second-line option for people whose pancreatic neuroendocrine tumors have spread to the liver. Blood markers identified in the study might one day help doctors pick the right treatment sooner.
- What could go wrong
- This is a mid-stage study of 80 people at one hospital, so results may not hold in a larger, more varied group. Lenvatinib and chemotherapy can cause side effects, and the blood markers may not reliably predict who responds.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Inclusion Criteria: * Age 18 to 75 years. * Histologically or cytologically confirmed pancreatic neuroendocrine tumor. * Radiologically confirmed liver metastases. * Disease progression or treatment failure after first-line systemic therapy, with eligibility for second-line treatment. * At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate hematologic, hepatic, and renal function as assessed by the investigator. * Life expectancy of at least 12 weeks. * Ability to understand and willingness to sign a written informed consent form. Exclusion Criteria: * Poorly differentiated neuroendocrine carcinoma or neuroendocrine tumor originating from a site other than the pancreas. * Previous treatment with lenvatinib. * Uncontrolled or clinically significant cardiovascular disease, including uncontrolled hypertension. * Active severe infection or other uncontrolled serious systemic disease. * Known central nervous system metastases that are symptomatic or uncontrolled. * Pregnancy or breastfeeding. * Participation in another interventional clinical study that may interfere with the outcomes of this study. * Any other condition that, in the opinion of the investigator, may make the participant unsuitable for participation in this study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pancreatic neuroendocrine tumor with liver metastases are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Chinese Academy of Medical Sciences，Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100000, China